In contrast, by utilizing technology-driven tools more effectively, we can drive efficiencies, improve communication, and ...

Jeneen Donadeo, executive director of portfolio management at TransCelerate, and Laura Galuchie, senior director and ...

Takeda has announced the completion of its 7-year, Phase III TIDES clinical trial (NCT02747927) evaluating the dengue vaccine, Qdenga. Along with an exploratory analysis of a booster dose, TIDES data ...

Now, with the MATTERHORN data, we’ve seen that when we start with Imfinzi—or an IO—in a perioperative setting, which ...

In today’s ACT Brief, we explore how Eli Lilly’s orforglipron could become the first oral GLP-1 therapy reviewed under FDA’s new national priority program, and examine emerging regulatory and ethical ...

Because the data [are] contextualized, we know who the physicians are [that are] working with the patients we aspire to treat ...

In today’s ACT Brief, we spotlight the industry’s push to reduce site technology burden, AstraZeneca’s broad survival gains ...

Explore how AstraZeneca’s immuno-oncology strategy focuses on improving survival in hard-to-treat cancers and moving checkpoint inhibitors into curative-intent settings.

Welcome to this special recap of this year’s SCRS Global Site Solutions Summit, where industry leaders gathered to share insights on strengthening collaboration between sponsors, CROs, and sites. The ...

Addressing the imbalance in clinical trial workloads by empowering mid-level investigators and using AI to expand access to ...

Gain insight into how the MATTERHORN trial’s results across PD-L1 subgroups could expand access to immunotherapy and reshape ...

ACT: The MATTERHORN trial showed a 22% reduction in the risk of death with the Imfinzi regimen. How significant is this ...